Completed
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
NCT02580591
- Conditions
- Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +5 more
- Locations
-
- Healthscan Clinical Trials LLC Montgomery, Alabama, United States
- John Muir Physician Network Clinical Research Center Concord, California, United States
- Valley Research Fresno, California, United States
- Marin Endocrine Care and Research Greenbrae, California, United States